ISDA

Deposition Date 2019-12-10

Release Date 2020-01-01

Last Version Date 2024-06-19

Entry Detail

PDB ID:

6TNS

Keywords:

TRANSFERASE

Title:

PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2 benzofuran5yl)pyridin3yl]ethane1 sulfonamide

Biological Source:

Source Organism:

Mus musculus (Taxon ID: 10090)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.24

R-Value Work:

0.18

R-Value Observed:

0.19

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Gene (Uniprot):Pik3cd
Chain IDs:A
Chain Length:940
Number of Molecules:1
Biological Source:Mus musculus

UniProt ID:O35904 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.153

Ligand Molecules

NQ5

Primary Citation

Optimization of Orally Bioavailable PI3K delta Inhibitors and Identification of Vps34 as a Key Selectivity Target.

Henley, Z.A, Amour, A, Barton, N, Bantscheff, M, Bergamini, G, Bertrand, S.M, Convery, M, Down, K, Dumpelfeld, B, Edwards, C.D, Grandi, P, Gore, P.M, Keeling, S, Livia, S, Mallett, D, Maxwell, A, Price, M, Rau, C, Reinhard, F.B.M, Rowedder, J, Rowland, P, Taylor, J.A, Thomas, D.A, Hessel, E.M, Hamblin, J.N.Show

J.Med.Chem. 63 638 655 (2020)

PMID: 31855425 DOI: 10.1021/acs.jmedchem.9b01585

Abstact

Optimization of a lead series of PI3Kδ inhibitors based on a dihydroisobenzofuran core led to the identification of potent, orally bioavailable compound 19. Selectivity profiling of compound 19 showed similar potency for class III PI3K, Vps34, and PI3Kδ, and compound 19 was not well-tolerated in a 7-day rat toxicity study. Structure-based design led to an improvement in selectivity for PI3Kδ over Vps34 and, a focus on oral phramacokinetics properties resulted in the discovery of compound 41, which showed improved toxicological outcomes at similar exposure levels to compound 19.

Legend

Protein

Chemical

Disease

Primary Citation of related structures